Skip to main content

Table 3 External validation of model 4

From: In silico studies of some 2-anilinopyrimidine derivatives as anti-triple-negative breast cancer agents

NamepIC50VR1_DzvSpMin1_BhsC3SP3MOMIRYpredYpredYobs
264.06695.20291.845009.58144.1940− 0.1340
44.06505.81371.8685010.13914.1625− 0.1025
24.07507.38691.777709.73764.1063− 0.0364
84.091589.8251.8089010.00724.04290.0471
124.35507.04451.864809.74264.20900.1409
134.291135.8491.895419.58614.6054− 0.3154
234.44723.68671.862609.61934.20910.2308
304.77461.27321.917419.70764.65690.1131
254.1650.25831.792509.30874.1705− 0.0704